TopoTarget responds.
John L
JL
Parsons
D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002614:Chelating Agents / Q000191:economics* / Q000627:therapeutic use; D017277:Drug Approval; D016527:Drug Costs / Q000706:statistics & numerical data; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D011929:Razoxane / Q000191:economics* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D018943:Anthracyclines; D000970:Antineoplastic Agents; D002614:Chelating Agents; D011929:Razoxane